DGAP-Adhoc: Fresenius SE: successfully completes capital

Fresenius SE / Capital Increase

12.08.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Fresenius SE successfully completes capital increase 

The new Fresenius SE shares were successfully placed today. In connection
with the companys capital increase, 2,748,057 new ordinary shares were
issued at a price of  52.00 and 2,748,057 preference shares were issued at
a price of  53.00. The transaction has generated gross proceeds of approx.
 289 million, fully in line with Fresenius financing plan.

The new shares are expected to be included in the quotation of the existing
shares of Fresenius SE in the regulated market at the Frankfurt, Munich and
Düsseldorf stock exchanges. They have full dividend entitlement for the
fiscal year 2008.

Dr. Ulf Mark Schneider, Chairman of the Management Board of Fresenius SE
commented: 'The capital increase is a further component of the acquisition
financing for APP Pharmaceuticals. This acquisition provides attractive
growth opportunities for Fresenius Kabis existing product portfolio in
North America. At the same time, Fresenius Kabi achieves a leading position
in the global I.V. generics market. The successful placement of the new
shares reflects the confidence of the capital markets in our strategy. With
this placement, the entire equity financing of the APP Pharmaceuticals
acquisition has been completed within a few weeks.'

Deutsche Bank and Commerzbank acted as Joint Lead Managers and Joint
Bookrunners and WestLB as Joint Lead Manager for the offering.


Capital Increase Data
Issuer:
Fresenius SE

Transaction Structure:
Capital increase without subscription rights

Offering: 
2,748,057 new ordinary shares
2,748,057 new preference shares

Placement of Shares:
Private placement with German and international institutional investors 

Stock Exchanges:
Regulated Market Frankfurt (Prime Standard), Munich, Düsseldorf

Bank Consortium:
Joint Bookrunner:
Deutsche Bank AG, Commerzbank AG
Joint Lead Manager:
Deutsche Bank AG, Commerzbank AG, WestLB AG



The Management Board
Bad Homburg v.d.H., August, 12 2008

End of note
DGAP 12.08.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       Fresenius SE
              Else-Kröner-Straße 1
              61352 Bad Homburg v.d.H.
              Deutschland
Phone:        +49 (0)6172 608-2485
Fax:          +49 (0)6172 608-2488
E-mail:       ir-fre@fresenius.com
Internet:     www.fresenius.com
ISIN:         DE0005785638, DE0005785604
WKN:          578563, 578560
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf,
              München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg;
              Terminbörse EUREX
End of News                                     DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Fresenius SE: successfully completes capital increase
